From intravenous to subcutaneous pertuzumab/trastuzumab in breast cancer: Clinical and pharmacoeconomic drivers and barriers to switching
Mariangela Gaudio(Humanitas University), Alberto Zambelli, Vera Basilico(Humanitas Mater Domini), Rosalba Torrisi(IRCCS Humanitas Research Hospital), Domiziana Alaimo(University of Pavia), C. Benvenuti, Rita De Sanctis(Humanitas University), Nicla La Verde(ASST Fatebenefratelli Sacco), Greta Schivardi(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Benedetta Tinterri(Ministero della Salute), A. Floreani(Humanitas University), Isabella Lorenzetti(Humanitas Mater Domini), C. Crepaldi(Humanitas Mater Domini), Riccardo Gerosa(Humanitas University), Flavia Jacobs(Fondazione IRCCS Istituto Nazionale dei Tumori), Giuseppe Saltalamacchia, Fabio Conforti(Humanitas Gavazzeni), Antonella Panzardi(Humanitas University), Jacopo Canzian(Humanitas University), Armando Santoro(IRCCS Humanitas Research Hospital), Paolo Angelo Cortesi(IRCCS Istituto Auxologico Italiano), Giovambattista Roda’(Humanitas Mater Domini), Daniela Strada(IRCCS Humanitas Research Hospital), Rebecca Pedersini(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Gianpiero Rizzo(Policlinico San Matteo Fondazione)
Cited by 0
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
|JAMA|2014|569
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532